Natco Pharma Limited (NATCOPHARM) - Total Assets
Based on the latest financial reports, Natco Pharma Limited (NATCOPHARM) holds total assets worth Rs104.30 Billion INR (≈ $1.13 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NATCOPHARM net asset value for net asset value and shareholders' equity analysis.
Natco Pharma Limited - Total Assets Trend (2005–2025)
This chart illustrates how Natco Pharma Limited's total assets have evolved over time, based on quarterly financial data.
Natco Pharma Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Natco Pharma Limited's total assets of Rs104.30 Billion consist of 61.1% current assets and 38.9% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs539.00 Million | 25.2% |
| Accounts Receivable | Rs12.56 Billion | 14.6% |
| Inventory | Rs7.66 Billion | 8.9% |
| Property, Plant & Equipment | Rs26.57 Billion | 30.8% |
| Intangible Assets | Rs2.09 Billion | 2.4% |
| Goodwill | Rs574.00 Million | 0.7% |
Asset Composition Trend (2005–2025)
This chart illustrates how Natco Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NATCOPHARM market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Natco Pharma Limited's current assets represent 61.1% of total assets in 2025, an increase from 56.2% in 2005.
- Cash Position: Cash and equivalents constituted 25.2% of total assets in 2025, up from 16.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is property, plant & equipment at 30.8% of total assets.
Natco Pharma Limited Competitors by Total Assets
Key competitors of Natco Pharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351
|
China | CN¥3.34 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF21.61 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.22 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Natco Pharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.10 | 4.96 | 3.06 |
| Quick Ratio | 3.62 | 4.19 | 2.30 |
| Cash Ratio | 1.58 | 1.55 | 0.00 |
| Working Capital | Rs52.67 Billion | Rs39.93 Billion | Rs18.25 Billion |
Natco Pharma Limited - Advanced Valuation Insights
This section examines the relationship between Natco Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.10 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 25.0% |
| Total Assets | Rs86.31 Billion |
| Market Capitalization | $2.16 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Natco Pharma Limited's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Natco Pharma Limited's assets grew by 25.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Natco Pharma Limited (2005–2025)
The table below shows the annual total assets of Natco Pharma Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs86.31 Billion ≈ $933.39 Million |
+24.97% |
| 2024-03-31 | Rs69.06 Billion ≈ $746.89 Million |
+22.08% |
| 2023-03-31 | Rs56.57 Billion ≈ $611.83 Million |
+10.73% |
| 2022-03-31 | Rs51.09 Billion ≈ $552.53 Million |
+6.62% |
| 2021-03-31 | Rs47.92 Billion ≈ $518.23 Million |
+4.45% |
| 2020-03-31 | Rs45.88 Billion ≈ $496.15 Million |
+6.62% |
| 2019-03-31 | Rs43.03 Billion ≈ $465.36 Million |
+15.83% |
| 2018-03-31 | Rs37.15 Billion ≈ $401.77 Million |
+60.30% |
| 2017-03-31 | Rs23.18 Billion ≈ $250.64 Million |
+27.08% |
| 2016-03-31 | Rs18.24 Billion ≈ $197.24 Million |
+31.77% |
| 2015-03-31 | Rs13.84 Billion ≈ $149.68 Million |
+15.75% |
| 2014-03-31 | Rs11.96 Billion ≈ $129.31 Million |
+10.67% |
| 2013-03-31 | Rs10.80 Billion ≈ $116.84 Million |
+19.68% |
| 2012-03-31 | Rs9.03 Billion ≈ $97.63 Million |
+27.63% |
| 2011-03-31 | Rs7.07 Billion ≈ $76.49 Million |
+28.39% |
| 2010-03-31 | Rs5.51 Billion ≈ $59.58 Million |
+6.66% |
| 2009-03-31 | Rs5.17 Billion ≈ $55.86 Million |
+23.16% |
| 2008-03-31 | Rs4.19 Billion ≈ $45.36 Million |
+19.89% |
| 2007-03-31 | Rs3.50 Billion ≈ $37.83 Million |
+13.59% |
| 2006-03-31 | Rs3.08 Billion ≈ $33.30 Million |
+7.15% |
| 2005-03-31 | Rs2.87 Billion ≈ $31.08 Million |
-- |
About Natco Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; a… Read more